GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Rua Bioscience Ltd (NZSE:RUA) » Definitions » Cash Flow from Financing

Rua Bioscience (NZSE:RUA) Cash Flow from Financing : NZ$1.55 Mil (TTM As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Rua Bioscience Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the six months ended in Dec. 2024, Rua Bioscience received NZ$1.28 Mil more from issuing new shares than it paid to buy back shares. It received NZ$0.36 Mil from issuing more debt. It paid NZ$0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received NZ$0.00 Mil from paying cash dividends to shareholders. It spent NZ$0.05 Mil on other financial activities. In all, Rua Bioscience earned NZ$1.59 Mil on financial activities for the six months ended in Dec. 2024.


Rua Bioscience Cash Flow from Financing Historical Data

The historical data trend for Rua Bioscience's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rua Bioscience Cash Flow from Financing Chart

Rua Bioscience Annual Data
Trend Jun21 Jun22 Jun23 Jun24
Cash Flow from Financing
19.67 -0.21 -0.12 -0.10

Rua Bioscience Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only -0.07 -0.05 -0.05 -0.05 1.59

Rua Bioscience Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Rua Bioscience's Cash from Financing for the fiscal year that ended in Jun. 2024 is calculated as:

Rua Bioscience's Cash from Financing for the quarter that ended in Dec. 2024 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was NZ$1.55 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Rua Bioscience  (NZSE:RUA) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Rua Bioscience's issuance of stock for the six months ended in Dec. 2024 was NZ$1.43 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Rua Bioscience's repurchase of stock for the six months ended in Dec. 2024 was NZ$-0.15 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Rua Bioscience's net issuance of debt for the six months ended in Dec. 2024 was NZ$0.36 Mil. Rua Bioscience received NZ$0.36 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Rua Bioscience's net issuance of preferred for the six months ended in Dec. 2024 was NZ$0.00 Mil. Rua Bioscience paid NZ$0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Rua Bioscience's cash flow for dividends for the six months ended in Dec. 2024 was NZ$0.00 Mil. Rua Bioscience received NZ$0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Rua Bioscience's other financing for the six months ended in Dec. 2024 was NZ$-0.05 Mil. Rua Bioscience spent NZ$0.05 Mil on other financial activities.


Rua Bioscience Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Rua Bioscience's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Rua Bioscience Business Description

Traded in Other Exchanges
N/A
Address
1 Commerce Place, Awapuni, Gisborne, NZL, 4071
Rua Bioscience Ltd is a pharmaceutical company engaged in the production of cannabinoid medicines. The company caters to both domestic and international customers. It operates in one segment, being research and development and the sale of pharmaceutical products in Australia, Germany and New Zealand.

Rua Bioscience Headlines

No Headlines